Roberto Polakiewicz

Roberto Polakiewicz

  • Chief Scientific Officer
  • Ph.D., Hebrew University of Jerusalem
In his role as Chief Scientific Officer, Dr. Roby Polakiewicz has been responsible for Product and Technology innovation at Cell Signaling Technology (CST) since 2005. His leadership and direction have created the company's most valuable products and valuable intellectual property. Dr. Polakiewicz has driven the successful implementation of four generations of novel antibody platform technologies that have been critical to the success of CST. Dr. Polakiewicz's research interests span different fields including molecular and cell biology, signal transduction, and cancer. During his 25 years of experience in research and technology development, Dr. Polakiewicz has published approximately 65 peer-reviewed publications, and is a named inventor on numerous patents and patent applications.

Dr. Polakiewicz received his B.S. in Chemistry and Ph.D. in Molecular Biology from the Hebrew University of Jerusalem, and completed postdoctoral studies at the Whitehead Institute for Biomedical Research at M.I.T.

Selected Publications